ShareRoot Ltd (ASX:SRO) has entered a collaboration that will see its MediaConsent platform used in a cancer clinical trial setting.
The collaboration is with Cancer Trials Australia (CTA) and the medical project is being led by The Social Science (TSS).
The MediaConsent Medical project now has three health or medical research related collaborators being St Vincent’s Hospital, Melbourne, Neuroscience Trials Australia, and CTA.
The shared goal with the MediaConsent clinical collaboration is to demonstrate how ShareRoot’s technology protects patient data and privacy whilst supporting the advancement of clinical research.
READ: ShareRoot Ltd attracts new substantial shareholder who has accumulated a 6.8% stake
Project leader Michelle Gallaher said: “The value of data in medical research is only growing as we find better ways to access and use data.”
“I’m really pleased to see MediaConsent applied to accelerating medical research and opening new ways for patients and carers to contribute to research by donating their data.”
CTA’s CEO Kurt Lackovic said: “We recognise the changing interest and value placed on real world data and real world evidence by both global regulators and the biopharma industry in shaping new treatments and products.
A platform like this could really democratise and transform clinical trials, enabling so many more people to participate in research, particularly from remote and regional areas or migrant populations that find it typically difficult to participate in clinical trials.”
MediaConsent able to be beneficial in healthcare sector
By collaborating with ShareRoot, clinical researchers can use MediaConsent to access a variety of consented real world data and evidence, in one platform.
Data that may be able to be integrated into the MediaConsent Medical platform may be derived from a number of sources which the patient would give consent for researchers and clinicians to use.
This includes data from social media and the internet, digital health wearables, private and public health records and statistics.
This puts patients in control of their data and ensures clinical researchers are compliant with the growing data privacy legislation and regulations around the world.